Pricing Log in Create free account

AC Immune (ACIU) vs Fate Therapeutics, Inc. (FATE)

AC Immune and Fate Therapeutics, Inc. are both Biotechnology companies. AC Immune and Fate Therapeutics, Inc. are of similar size ($227.0M and $223.1M). Fate Therapeutics, Inc. grew revenue faster over the last twelve months: −23.4% against −78.6%. AC Immune has the higher net margin (−962.2% vs −1,941.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, AC Immune leads on 8 and Fate Therapeutics, Inc. on 7.

Valuation

Metric ACIU FATE Biotechnology median
P/E n/m n/m 10.60
P/S 21.29 34.13 9.40
P/B 4.52 1.44 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 9.06 14.04 9.02
Earnings yield (32.74%) (57.07%) (32.88%)
Free cash flow yield (55.75%) (47.59%) (23.13%)

Profitability

Metric ACIU FATE Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin (986.55%) (2,058.08%) 0.00%
Net margin (962.17%) (1,941.09%) 0.00%
Free cash flow margin 0.00% (1,624.06%) 0.00%
Return on equity (122.01%) (60.75%) (51.96%)
Return on assets (33.75%) (39.89%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ACIU FATE Biotechnology median
Revenue growth (TTM) (78.60%) (23.36%) 6.76%
EPS growth (last fiscal year) (44.83%) 29.88% 29.88%
Revenue growth, 5-year CAGR (47.84%) (26.71%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ACIU FATE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.85 4.85 4.97
Net debt to EBITDA 1.37 1.47 1.01

Dividend

Metric ACIU FATE Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ACIU FATE Biotechnology median
Market cap 226.96m 223.08m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack